GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Total Tax Payable

Biogen (BSP:BIIB34) Total Tax Payable

: R$1,261 Mil (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Biogen's Total Tax Payable for the quarter that ended in Dec. 2023 was R$1,261 Mil.

Biogen's quarterly Total Tax Payable declined from Jun. 2023 (R$1,262 Mil) to Sep. 2023 (R$1,204 Mil) but then increased from Sep. 2023 (R$1,204 Mil) to Dec. 2023 (R$1,261 Mil).

Biogen's annual Total Tax Payable increased from Dec. 2021 (R$988 Mil) to Dec. 2022 (R$1,363 Mil) but then declined from Dec. 2022 (R$1,363 Mil) to Dec. 2023 (R$1,261 Mil).


Biogen Total Tax Payable Historical Data

The historical data trend for Biogen's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Tax Payable
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.06 730.55 987.91 1,363.28 1,261.21

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Tax Payable Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,363.28 1,226.63 1,261.96 1,204.06 1,261.21

Biogen Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Biogen Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Biogen's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BSP:BIIB34) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines